Last update 01 Nov 2024

BPIFA1

Last update 01 Nov 2024

Basic Info

Synonyms

bA49G10.5, BPI fold containing family A member 1, BPI fold-containing family A member 1

+ [13]

Introduction

Lipid-binding protein which shows high specificity for the surfactant phospholipid dipalmitoylphosphatidylcholine (DPPC) (PubMed:25223608). Plays a role in the innate immune responses of the upper airways (PubMed:23499554, PubMed:23132494). Reduces the surface tension in secretions from airway epithelia and inhibits the formation of biofilm by pathogenic Gram-negative bacteria, such as P.aeruginosa and K.pneumoniae (PubMed:23499554, PubMed:23132494, PubMed:27145151). Negatively regulates proteolytic cleavage of SCNN1G, an event that is required for activation of the epithelial sodium channel (ENaC), and thereby contributes to airway surface liquid homeostasis and proper clearance of mucus (PubMed:24124190, PubMed:24043776). Plays a role in the airway inflammatory response after exposure to irritants (PubMed:11425234). May attract macrophages and neutrophils (PubMed:23132494).

Drugs associated with BPIFA1

ELD-607

Target

BPIFA1 x ORAI1

Mechanism

BPIFA1 stimulators [+1]

Active Org.

Eldec Pharmaceuticals, Inc.

Originator Org.

Eldec Pharmaceuticals, Inc.

Active Indication

Enterobacter Infection [+5]

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

100 Clinical Results associated with BPIFA1

100 Translational Medicine associated with BPIFA1

0 Patents (Medical) associated with BPIFA1

277

Literatures (Medical) associated with BPIFA1

01 Nov 2024·Cell Calcium

ELD607 specifically traffics Orai1 to the lysosome leading to inhibition of store operated calcium entry

Article

Author: Wrennall, Joe A ; Tarran, Robert ; Flori Sassano, M ; Goriounova, Alexandra S

Orai1 is a plasma membrane Ca²⁺ channel involved in store operated calcium entry (SOCE). SOCE can regulate cell growth, exocytosis, gene expression and inflammation. We previously found that short palate lung and nasal epithelial clone 1's (SPLUNC1) sixth α-helix (α6) bound Orai1 to inhibit SOCE. SPLUNC1 was not proteolytically stable, so we developed ELD607, an 11 amino acid peptide based on SPLUNC1's α6 region which was more stable and more potent than SPLUNC1/α6. Here, we studied ELD607's mechanism of action. We overexpressed either Orai1-HA or Orai1-YFP in HEK293T cells to probe ELD607-Orai1 interactions by confocal microscopy. We also measured changes in Fluo-4 fluorescence in a multiplate reader as a marker of cytoplasmic Ca²⁺ levels. ELD607 internalized Orai1 independently of STIM1. Both 15 min and 3 h exposure to ELD607 similarly depleted Orai1 in the plasma membrane. However, 3 h exposure to ELD607 yielded greater inhibition of SOCE. ELD607 continued to colocalize with Orai1 after internalization and this process was dependent on the presence of the ubiquitin ligase NEDD4.2. Similarly, ELD607 increased the colocalization between Orai1 and ubiquitin. ELD607 also increased the colocalization between Orai1 and Rab5 and 7, but not Rab11, suggesting that Orai1 trafficked through early and late but not recycling endosomes. Finally, ELD607 caused Orai1, but not Orai2, Orai3, or STIM1 to traffic to lysosomes. We conclude that ELD607 rapidly binds to Orai1 and works in an identical fashion as full length SPLUNC1 by internalizing Orai1 and sending it to lysosomes, leading to a decrease in SOCE.

01 Oct 2024·International Journal of Rheumatic Diseases

BPIFA1 alleviates allergic rhinitis by regulating the NF‐κB signaling pathway and Treg/Th17 balance

Article

Author: Yang, Ying ; Xu, Hongyan ; Li, Shidong

AbstractAimAllergic rhinitis (AR) is an allergic condition characterized by inflammation of the nasal mucosa. Bacterial permeability‐increasing family member A1 (BPIFA1) exhibits anti‐inflammatory properties; however, its impact on AR remains unclear. Aim of this study is to investigate the expression and function of BPIFA1 in AR and its influence on inflammation and immune regulation in a mouse model of AR induced by ovalbumin (OVA).MethodsThe expression of BPIFA1 was analyzed using quantitative real‐time PCR (qRT‐PCR) and immunohistochemistry (IHC). Morphological assessments of nasal mucosal tissues were conducted. Levels of inflammatory mediators in nasal lavage fluid (NALF) and serum were quantified using enzyme‐linked immunosorbent assay (ELISA) kits. Protein expressions of BPIFA1, phosphorylated and total p65 (p‐p65/p65), and IκBα were evaluated through Western blot analysis. The total cell counts, including epithelial cells, eosinophils, and lymphocytes in NALF, were determined using a hemocytometer. A mouse model of AR was established by OVA management.ResultsBPIFA1 expression was found to be reduced in the nasal mucosa tissues of patients with AR, suggesting a potential role in the disease's progression. We successfully developed a mouse model of AR, where BPIFA1 was similarly downregulated, indicating its possible involvement in modulating the NF‐κB signaling pathway. Overexpression of BPIFA1 in this model attenuated inflammation and allergic responses by inhibiting the NF‐κB pathway. Additionally, overexpression of BPIFA1 promoted the differentiation of regulatory T cells (Treg) and inhibited the differentiation of T helper 17 cells (Th17) in the NALF of AR mice, further demonstrating its regulatory impact on immune responses. The study confirmed that BPIFA1 upregulation reduced the levels of inflammatory cytokines TNF‐α and IL‐6, decreased infiltration of inflammatory cells, and modulated antigen‐specific immunoglobulin levels and histamine in serum.ConclusionBPIFA1 mitigated both inflammatory and allergic responses in AR mice induced by OVA through the modulation of the NF‐κB signaling pathway and the balance between regulatory T cells (Treg) and T helper 17 cells (Th17). These findings suggest that BPIFA1 could serve as a novel biomarker and therapeutic target for AR, offering potential for the development of targeted treatments to improve patient outcomes.

13 May 2024·Biomacromolecules

Correction to “Lung SPLUNC1 Peptide Derivatives in the Lipid Membrane Headgroup Kill Gram-Negative Planktonic and Biofilm Bacteria”

Author: Vijai, Aishwarya ; Gong, Yuqi ; Di, Yuan-Pu ; Qin, Weiheng ; Kang, Ann ; Mitra, Saheli ; Lin, Qiao ; Chen, Jespar ; Tristram-Nagle, Stephanie ; Jakkampudi, Tanvi ; Wang, Runxuan ; Ryan, Emma ; Heinrich, Frank ; Song, Junming

SPLUNC1 (short palate lung and nasal epithelial clone 1) is a multifunctional host defense protein found in human respiratory tract with antimicrobial properties.In this work, we compare the biol. activities of four SPLUNC1 antimicrobial peptide (AMP) derivatives using paired clin. isolates of the Gram-neg. (G(-)) bacteria Klebsiella pneumoniae, obtained from 11 patients with/without colistin resistance.Secondary structural studies were carried out to study interactions between the AMPs and lipid model membranes (LMMs) utilizing CD (CD).Two peptides were further characterized using X-ray diffuse scattering (XDS) and neutron reflectivity (NR).A4-153 displayed superior antibacterial activity in both G(-) planktonic cultures and biofilms.NR and XDS revealed that A4-153 (highest activity) is located primarily in membrane headgroups, while A4-198 (lowest activity) is located in hydrophobic interior.CD revealed that A4-153 is helical, while A4-198 has little helical character, demonstrating that helicity and efficacy are correlated in these SPLUNC1 AMPs.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

BPIFA1

Basic Info

Related

Analysis